A Narrative Review on the Administration of Inhaled Prostaglandins in Critically Ill Adult Patients With Acute Respiratory Distress Syndrome

• Published in: The Annals of pharmacotherapy Vol. 58; no. 5; p. 533
• Main Authors: Ware, Lydia R, Kim, Christine S, Szumita, Paul M, DeGrado, Jeremy R
• Format: Journal Article
• Language: English
• Published: United States 01.05.2024
• Subjects: COVID-19; acute respiratory distress syndrome; critical care; inhaled prostaglandins; epoprostenol
• ISSN: 1542-6270
• DOI: 10.1177/10600280231194539

To describe the effect of inhaled prostaglandins on both oxygenation and mortality in critically ill patients with acute respiratory distress syndrome (ARDS), with a focus on safety and efficacy in coronavirus disease 2019 (COVID-19)-associated ARDS and non-COVID-19 ARDS. A literature search of MEDLINE was performed using the following search terms: , , , All abstracts were reviewed. Relevant English-language reports and studies conducted in humans between 1980 and June 2023 were considered. Data regarding inhaled prostaglandins and their effect on oxygenation are limited but show a benefit in patients who respond to therapy, and data pertaining to their effect on mortality is scarce. Concerns exist regarding the formulation of inhaled epoprostenol (iEPO) utilized in addition to modes of medication delivery; however, the limited data surrounding their use have shown a reasonable safety profile. Other avenues and beneficial effects may exist with inhaled prostaglandins, such as use in COVID-19-associated ARDS or non-COVID-19 ARDS patients undergoing noninvasive mechanical ventilation or during patient transport. The use of inhaled prostaglandins can be considered in critically ill patients with COVID-19-associated ARDS or non-COVID-19 ARDS who are experiencing difficulties with oxygenation refractory to nonpharmacologic strategies. The use of iEPO and other inhaled prostaglandins requires further investigation to fully elucidate their effects on clinical outcomes, but it appears these medications may have a potential benefit in COVID-19-associated ARDS and non-COVID-19 ARDS patients with refractory hypoxemia but with little effect on mortality.